 - Patients must have received at least two prior anti-MM treatments. The prior treatments must include at least one IMiD thalidomide or lenalidomide and bortezomib. If patients are unable to tolerate thalidomide or lenalidomide they can be included without prior IMiD treatment. Patients may be included if they did not experience grade III neuropathy while on bortezomib. Patients may have previously received autologous or peripheral blood stem cell transplantation. 